What FK Biotecnologia does

FK Biotecnologia S.A. (operating as FK Biotec) is a clinical-stage Brazilian biotechnology company founded in 1999 by Fernando Thomé Kreutz, headquartered in Porto Alegre, Rio Grande do Sul, Brazil. The company develops personalized cancer immunotherapies built around its proprietary CTAA (Células Tumorais Apresentadoras de Antígeno) platform, which processes each patient's own tumor cells — treated with human interferon-gamma (hIFN-y) — into antigen-presenting tumor cells that express MHC Class II molecules. This mechanism activates CD4+ helper T cells and drives a multi-neoantigen immune response against residual cancer. The platform is protected by an extensive patent portfolio granted in 10 countries (Belgium, Germany, Netherlands, England, Brazil, Ireland, Switzerland, France, Japan, and the United States), with protection extending until 2038.

The company's clinical focus is on prostate cancer patients at higher risk of recurrence following prostatectomy, and it currently conducts Phase I and Phase II clinical trials in Brazil through partnerships with academic and medical institutions including the Instituto Nacional de Nanobiotecnologia (UnB), the Instituto Nacional de Pesquisa em Medicina (UFRGS), and the Projeto CABBIO (Centro Brasil-Argentina de Biotecnologia) under CNPq sponsorship. As a pre-commercial clinical-stage biotech, FK Biotec generates no disclosed product revenue; its business model is oriented toward eventual commercialization through direct sales to hospitals and oncology centers, or through licensing arrangements with pharmaceutical partners. The company was among the first Brazilian biotech firms to receive venture capital investment, though only one disclosed funding round ($338,741 from CRP Companhia de Participações in October 2000) is on record.

Name

FK Biotecnologia

Legal name

FK Biotecnologia S.A.

Website

https://fkbiotech.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

FK Biotecnologia is a clinical-stage Brazilian biotechnology company developing personalized cancer immunotherapies via its patented CTAA platform, using patients' own tumor cells to target prostate cancer patients at high risk of post-prostatectomy recurrence.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Medical Oncology (HLAKAFAB)

Keywords

• Personalized cancer immunotherapy
• Cell-based cancer vaccines
• Oncology clinical trials
• Biopharmaceutical drug development
• Prostate cancer therapeutics

Headquarters

HQ city

Porto Alegre

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Personalized Cancer Immunotherapy: As a clinical-stage biotechnology company developing personalized therapeutic cancer vaccines, FK Biotec generates revenue through the development and potential future commercialization of personalized CTAA immunotherapies. The company is in Phase I/II clinical trials in Brazil, indicating a pre-commercial or early commercial stage focused on research and development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

FK Biotecnologia develops and manufactures personalized cancer immunotherapies using its proprietary CTAA (Células Tumorais Apresentadoras de Antígeno) platform. The therapy processes a patient's own tumor cells to create Antigen Presenting Tumor Cells that stimulate a multi-neoantigen immune response, currently focused on prostate cancer patients at high risk of recurrence after prostatectomy in Phase I and Phase II clinical trials in Brazil.

Product overview

FK Biotecnologia offers a single unified product: the Células Tumorais Apresentadoras de Antígeno (CTAA) personalized cancer immunotherapy platform. This proprietary patented technology (patents extending to 2038) creates individualized therapeutic vaccines from each patient's own tumor cells, which are processed to express MHC Class II and activate CD4+ helper T cells, generating a multi-neoantigen immune response. The company is conducting Phase I and Phase II clinical trials in Brazil. The CTAA platform represents the entirety of the company's product and service offering—a personalized cell-based cancer therapeutic.

Differentiator

Problem solved

Functional benefit

Products and services

• Células Tumorais Apresentadoras de Antígeno (CTAA) A personalized cancer immunotherapy that uses each patient's own tumor cells, processed and activated to create Antigen Presenting Tumor Cells (CTAA), which stimulate a multi-neoantigen immune response against cancer cells. Currently in Phase I and Phase II clinical trials in Brazil, targeting prostate cancer patients at high risk of recurrence after prostatectomy.

Quantifiable outcome

• Clinically significant response in prostate cancer patients treated with personalized CTAA immunotherapy

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Instituto Nacional de Nanobiotecnologia (UnB)coreStrategic or Co-development PartnerAcademic partnership with the National Institute of Nanobiotechnology at University of Brasília for research and development collaboration in biotechnology.
• Instituto Nacional de Pesquisa em Medicina (UFRGS)coreStrategic or Co-development PartnerResearch partnership with the National Institute of Research in Medicine at Federal University of Rio Grande do Sul for medical research collaboration.
• Projeto CABBIO (Centro Brasil-Argentina de Biotecnologia) - CNPqcoreStrategic or Co-development PartnerInternational collaborative research project between Brazil and Argentina in biotechnology, supported by CNPq (National Council for Scientific and Technological Development). This partnership enables cross-border research collaboration in the biotechnology sector.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Dendreon: Dendreon developed sipuleucel-T (Provenge), the first FDA-approved autologous cellular immunotherapy for prostate cancer. It is the most directly comparable company to FK Biotec because both use a patient's own antigen-presenting cells to stimulate an immune response against prostate cancer.
• Moderna: Moderna is developing personalized mRNA-based neoantigen cancer vaccines (e.g., mRNA-4157/V940 in combination with Keytruda). It is a direct competitor in personalized cancer immunotherapy and brings large-scale development capabilities FK Biotec lacks.
• BioNTech: BioNTech is a leading developer of personalized neoantigen cancer vaccines using mRNA technology (e.g., BNT122/Autogene cevumeran). It competes directly with FK Biotec's CTAA in the personalized, multi-neoantigen cancer immunotherapy category, with significantly greater capital and clinical resources.
• Imvax: Imvax develops personalized, autologous whole-tumor cell immunotherapies (e.g., IGV-001 for glioblastoma). It is highly comparable to FK Biotec in using patient-derived tumor cells to create individualized immunotherapies targeting solid tumors.
• Iovance Biotherapeutics: Iovance develops autologous tumor-infiltrating lymphocyte (TIL) therapies for solid tumors (e.g., lifileucel). It is comparable to FK Biotec as an autologous cell therapy developer for solid tumor indications, though using TILs rather than APC tumor cells.
• Gritstone bio: Gritstone bio develops neoantigen-based immunotherapies, including personalized cancer vaccines using prime-boost platforms. It is comparable to FK Biotec as an emerging direct competitor in personalized, multi-neoantigen cancer immunotherapy.
• Adaptimmune Therapeutics: Adaptimmune develops personalized cell therapies using engineered TCR-T cells, including affinity-tuned autologous products. It is a direct competitor in personalized cell therapy for cancer, with deeper clinical and commercial capabilities.

Broad incumbents

• Merck & Co. Merck leads immuno-oncology with Keytruda and is actively partnering with personalized cancer vaccine developers (Moderna, others). It is a relevant incumbent peer because its combination strategy with personalized vaccines frames the competitive and partnering context for FK Biotec's CTAA.
• Bristol-Myers Squibb: BMS is a major oncology incumbent with broad immuno-oncology capabilities (Opdivo, Yervoy) and active cell therapy investments. It represents the type of large pharma partner that FK Biotec would need to scale globally and is a potential acquirer or licensor.

Emerging players

• Nkarta: Nkarta develops allogeneic and autologous NK cell therapies for cancer, overlapping with FK Biotec's cell therapy modality for oncology. It is comparable as a clinical-stage cell therapy developer, though mechanistically distinct (NK cells vs. APC tumor cells).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/388871234572413

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FK Biotecnologia